Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from INmune Bio

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge?

INmune Bio Inc. (NASDAQ:INMB) stock surged by 24.72% in after-hours trading on Friday. The company announced a novel selective soluble TNF inhibitor, which is likely to have influenced the stock’s performance.

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022

The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours:

A Preview Of INmune Bio's Earnings

INmune Bio (NASDAQ:INMB) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that INmune Bio will report an earnings per share (EPS) of $-0.64.

INmune Bio's Return On Capital Employed Insights

INmune Bio (NASDAQ:INMB) brought in sales totaling $163.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 2.25%, resulting in a loss of $9.67 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

INmune Bio: Q4 Earnings Insights

INmune Bio: Q4 Earnings Insights

INmune Bio (NASDAQ:INMB) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings INmune Bio beat estimated earnings by 5.17%, reporting an EPS of $-0.55 versus an estimate of $-0.58.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Prudential Financial

Travelers Companies

Genocea Biosciences

CASI Pharmaceuticals

Reinsurance Group

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play